KYMR

Nello Mainolfi

Known title: Chief Executive OfficerCIK: 0001821189

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 16, 2026

Raymond James initiates coverage on Kymera with Outperform rating. Raymond James has started covering Kymera Therapeutics, assigning an Outperform rating and a price target of $140. This new analyst note adds to the current consensus, which has an average target of $139.35 from 23 analysts. Recent discussions also question whether the company's pipeline is over-hyped or developing into a major therapeutic success.

this person other insiders at KYMR

Transaction History

KYMR▲ Buy$62K
KYMR▼ Sell$393K
KYMR▼ Sell$619K
KYMR▼ Sell$552K
KYMR▼ Sell$870K
KYMR▼ Sell$950K
KYMR▼ Sell$30K
KYMR▲ Buy$104K
KYMR▼ Sell$6.0M
KYMR▲ Buy$166K
KYMR▼ Sell$212K
KYMR▼ Sell$755K
KYMR▼ Sell$5.1M
KYMR▼ Sell$389K
KYMR▼ Sell$2.8M
KYMR▲ Buy$62K
KYMR▼ Sell$1.4M
KYMR▼ Sell$77K
KYMR▼ Sell$985K
KYMR▲ Buy$62K
KYMR▼ Sell$491K
KYMR▼ Sell$302K
KYMR▼ Sell$139K
KYMR▼ Sell$748
KYMR▼ Sell$1.8M
KYMR▲ Buy$100K
KYMR▲ Buy$62K
KYMR▼ Sell$1.9M
KYMR▼ Sell$472K
KYMR▲ Buy$100K
KYMR▲ Buy$208K
KYMR▼ Sell$8.9M
KYMR▲ Buy$62K
KYMR▼ Sell$111K
KYMR▼ Sell$1.5M
KYMR▼ Sell$223K
KYMR▲ Buy$62K
KYMR▼ Sell$1.5M
KYMR▲ Buy$62K
KYMR▼ Sell$1.5M
KYMR▲ Buy$21K
KYMR▲ Buy$100K
KYMR▲ Buy$30K
KYMR▲ Buy$19K
KYMR▲ Buy$5K
KYMR▲ Buy$37K
KYMR▲ Buy$25K
KYMR▲ Buy$21K
KYMR▲ Buy$58K
KYMR▲ Buy$67K
KYMR▲ Buy$42K
KYMR▲ Buy$21K
KYMR▲ Buy$18K
KYMR▼ Sell$140K
KYMR▼ Sell$209K
KYMR▼ Sell$86K
KYMR▼ Sell$13K
KYMR▼ Sell$533K
KYMR▼ Sell$19K
KYMR▲ Buy$35K
KYMR▼ Sell$362K
KYMR▲ Buy$47K
KYMR▼ Sell$393K
KYMR▼ Sell$569K
KYMR▼ Sell$229K
KYMR▼ Sell$6K
KYMR▲ Buy$17K
KYMR▲ Buy$13K
KYMR▼ Sell$306K
KYMR▼ Sell$41K
KYMR▼ Sell$532K
KYMR▲ Buy$86K
KYMR▼ Sell$1.2M
KYMR▼ Sell$119K
KYMR▼ Sell$469K
KYMR▼ Sell$40K
KYMR▼ Sell$17K
KYMR▲ Buy$25K

We use analytics to understand how market-wall is used. No personal data is sold.